Ongoing Studies

We are heavily involved in research on depression, post-traumatic stress disorder, and other mood and anxiety conditions. While we focus many of our current studies on novel therapeutics, we also design studies to help us understand the development, progression, and/or course of a given illness. We cannot always offer you a specific treatment, but we hope that your participation in our research might at least inform our understanding of the nature of mood and anxiety disorders. As participants, you make critical contributions to our ability to understand how mood and anxiety disorders work. We know many people come to us hoping to feel better; we do our best to help those who do. Even if we can’t offer you treatment, we hope you will seriously consider participating in one of our studies. Your participation may make it possible for us to help someone with a condition much like yours in the future.

Below is a list of our currently active studies, organized by treatment area or problem.

PCORI ELEKT-D: ECT vs Ketamine Trial

PI: James Murrough, MD, PhD   

Study Coordinator: Abigail Collins

Funding: Patient Centered Outcomes Research Institute (PCORI)

Description: This is a multi-site randomized trial of electroconvulsive therapy (ECT) versus Ketamine for patients with treatment resistant depression (TRD). Patients will be randomized to receive ECT 3 times per week or ketamine 2 times per week over the course of 3-5 weeks.

Main Inclusion: Primary MDD (unipolar) diagnosis, at least 2 trials of antidepressants and/or augmentation strategies, willing to receive either ECT or ketamine, medically healthy, between ages 21-75

Main Exclusion: Bipolar Disorders, psychotic symptoms in the current episode, diagnosis of a psychotic disorder

Study Participation Length: acute phase 4 weeks, follow up 6 months

Compensation: Yes

Clinicaltrials.gov ID: NCT03113968 

 

Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

PI: Manish Jha, MD

Study Coordinator: Morgan Harnois   

Funding: Acadia Pharmaceuticals

Description: This is a multi-site randomized trial of electroconvulsive therapy (ECT) versus Ketamine for patients with treatment resistant depression (TRD). Patients will be randomized to receive ECT 3 times per week or ketamine 2 times per week over the course of 3-5 weeks.

Main Inclusion: at least 18 years old, current MDD diagnosis, currently taking one SSRI or SNRI anti-depressant 

Main Exclusion: Bipolar Disorders, psychotic symptoms in the current episode, diagnosis of a psychotic disorder, cardiac disorders

Study Participation Length: acute phase 6 weeks, follow up 3 weeks

Compensation: Yes

Clinicaltrials.gov ID: NCT03999918

 

7T MRI to reveal structural, connectomic and metabolic imaging markers for the neurobiology of Depression

PI: Priti Balchandani, PhD

Study Coordinator: Sarah Rutter

Funding: National Institute of Mental Health

Description: The purpose of this study is to develop and apply a comprehensive 7 Tesla MRI protocol to better understand brain function in mood disorders such as depression. We expect to learn the best use of this new technology in finding and defining suspected disease of normal anatomy and function.

Inclusion: 18 – 65 years old, Healthy volunteers OR Patients in a current major depressive episode

Exclusion: Lifetime history of psychotic features, diagnosis of schizophrenia, diagnosis of bipolar disorder, MRI contraindications (e.g. metal in the body), Individuals currently taking antidepressant medication

Study Participation Length: Two 2-3 hour visits.

Compensation: Yes

 

Real-time biofeedback with 7-Tesla MRI for neurocircuit based treatment of depression

PI: Laurel Morris

Study Coordinator: Morgan Harnois

Funding: Brain and Behavior Research Fund

Description: The purpose of this study is to investigate whether brain-computer interface (BCI) technology can help improve depression symptoms. Participants will undergo an fMRI brain scan during which they will train to use certain thoughts to increase activity within a specific area of the brain.

Inclusion: 18 – 65 years old, Patients in a current major depressive episode

Exclusion: Lifetime history of psychotic features, diagnosis of schizophrenia, diagnosis of bipolar disorder, MRI contraindications (e.g. metal in the body), Individuals currently taking antidepressant medication

Study Participation Length: Up to 5 weeks

Compensation: Yes

 

Neuro-Immune Biotypes of Depression: Towards Pathophysiology-Based Diagnosis and Personalized Treatment

PI:  James Murrough, MD, PhD   

Study Coordinator: Abigail Collins

Funding: Charles A. Dana Foundation

Description: The current study aims to integrate advanced assessments of the brain, the immune system and of clinical symptoms in patients with major depressive disorder (MDD) in order to ultimately understand whether there are unique subgroups of MDD. Other recent studies suggest that stress impacts the blood-brain barrier (BBB), which is a protective barrier between the brain and the blood. BBB damage caused by stress might allow certain immune system proteins to enter the brain that wouldn't normally. This infiltration might alter brain activity and may lead to MDD. This study will use advanced brain imaging techniques at the 7T level (magnetic resonance imaging, MRI) to understand the relationships between BBB damage, the immune system and brain function in MDD and healthy non-depressed volunteers. If successful, the proposed project will advance our understanding of MDD and may point out specific sub-groups of MDD that may benefit from more specific treatments.

Inclusion criteria: Male or female from 18-55 years who meet DSM-V criteria unipolar major depressive disorder OR Healthy Volunteers who do not meet for any current or past psychiatric diagnoses as defined by DSM-V criteria;       

Exclusion criteria: Diagnosis psychotic disorder, neurodevelopmental disorder, or neurocognitive disorder, current use of any psychiatric medication, any diagnosed inflammatory or autoimmune disorder, any contraindications to MRI

Study Participation Length: Up to 4 weeks (2-3 visits)

Compensation: Yes

 

 

Stress and Atherosclerotic Plaque Macrophages: A Systems Biology Approach – PET/MRI of the Brain-Hematopoiesis-Atherosclerosis Axis in PTSD Patients

PI: Zahi Fayad, PhD and James Murrough, MD, PhD

Study Coordinator: Vicki Soogrim

Funding: National Institute of Health

Description: This is a two-center five-year prospective observational study examining the effect of PTSD on vascular inflammation, proliferation, and plaque burden. The study centers will be TMII at Mount Sinai and the Athinoula A. Martinos Center for Biomedical Imaging at MGH. This Project will include two study visits: one screening visit and one imaging visit, to be completed in two different days and within 4 weeks apart.

Three groups of individuals will be recruited:

  • Group 1 includes diagnosed PTSD subjects from at least 1 year prior to enrollment
  • Group 2 (trauma control group) includes control subjects who have been exposed to trauma without developing PTSD symptoms from at least 1 year prior to enrollment
  • Group 3 (healthy control group) individuals who have neither PTSD nor exposure to trauma

Main Inclusion:

  1. Male or female aged 30-65 years
  2. Does not meet for any current or past psychiatric diagnoses as defined by DSM-V criteria (Healthy Control)OR Meets DSM-V criteria for PTSD from at least 1 year prior to enrollment (PTSD) OR meets DSM-V criteria A of PTSD without satisfying criteria for a PTSD diagnoses according to the DSM-V from at least 1 year prior to enrollment (Trauma Control)
  3. Have a level of understanding of the English language sufficient to agree to all tests and examinations required by the study and must be able to participate fully in the informed consent process

Main Exclusion: Clinical history of atherosclerotic disease (prior myocardial infarction, stroke, peripheral artery disease) or any contraindications to MRI, including claustrophobia, any trauma or surgery which may have left magnetic material in the body, magnetic implants or pacemakers, and inability to lie still for 1 hour or more.

Study Participation Length: 2 Visits

Compensation: Yes    

Randomized Controlled Trial of Repeated Dose Intravenous Ketamine for PTSD

PI: Adriana Feder, MD

Study Coordinator: Sarah Rutter

Funding: Ichan School of Medicine at Mount Sinai and NARSAD

Description: We are studying whether ketamine, when given repeatedly intravenously (into a vein) can produce a quick and persistent improvement in PTSD symptoms. We are comparing the effects of ketamine with those of midazolam, which has similar acute anesthetic effects compared to ketamine but has not been shown to treat or alleviate any symptoms of PTSD. This makes midazolam an appropriate substance to gauge whether ketamine can treat or alleviate PTSD symptoms thereby acting as what we call an active control.

Main Inclusion: Primary chronic PTSD diagnosis, between 18-65 years old

Main Exclusion: Lifetime history of psychotic features, diagnosis of schizophrenia, diagnosis of bipolar disorder, any clinically significant axis II disorder, current eating disorder, drug or alcohol abuse/dependence within preceding year, serious unstable medical illnesses

Study Participation Length: Approximately 1 –1.5 months

Compensation for all study visits: Yes

Clinicaltrials.gov: NCT02397889 

Transdiagnostic Multimodal 7 Tesla MRI of the Locus Coeruleus in Human Pathological Anxiety

PI: James Murrough, MD, PhD

Study Coordinator: Vicki Soogrim

Funding: National Institute of Health

Description: The purpose of this research study is investigate the brain processes underlying anxiety disorders. In this particular study, we aim to further our understanding about a part of the brain called the locus coeruleus (LC) by running the first high-resolution 7-Tesla (7T) MRI study of this structure in patients with anxiety. The LC is important to study because it plays a big role in the brains response to stressful situations. If successful, this study will provide the first study of the human LC system in patients with anxiety. We anticipate this work will help to diagnose anxiety disorders and provide new routes for treatments.

Main Inclusion: Primary chronic PTSD diagnosis, between 18-65 years old

Main Exclusion: Lifetime history of psychotic features, diagnosis of schizophrenia, diagnosis of bipolar disorder, any clinically significant axis II disorder, drug or alcohol abuse/dependence within preceding year, serious unstable medical illnesses, ) or any contraindications to MRI, including claustrophobia

Study Participation Length: 1-3 study visits with each visit lasting 3-7 hours. If the study is completed in 2 or 3 visits, these visits will need to be within 1 month of each other.

Compensation for all study visits: Yes

Transdiagnostic Multimodal 7 Tesla MRI of the Locus Coeruleus in Human Pathological Anxiety

PI: James Murrough, MD, PhD

Study Coordinator: Vicki Soogrim

Funding: National Institute of Health

Description: The purpose of this research study is investigate the brain processes underlying anxiety disorders. In this particular study, we aim to further our understanding about a part of the brain called the locus coeruleus (LC) by running the first high-resolution 7-Tesla (7T) MRI study of this structure in patients with anxiety. The LC is important to study because it plays a big role in the brains response to stressful situations. If successful, this study will provide the first study of the human LC system in patients with anxiety. We anticipate this work will help to diagnose anxiety disorders and provide new routes for treatments.

Main Inclusion: Primary chronic PTSD diagnosis, between 18-65 years old

Main Exclusion: Lifetime history of psychotic features, diagnosis of schizophrenia, diagnosis of bipolar disorder, any clinically significant axis II disorder, drug or alcohol abuse/dependence within preceding year, serious unstable medical illnesses, ) or any contraindications to MRI, including claustrophobia

Study Participation Length: 1-3 study visits with each visit lasting 3-7 hours. If the study is completed in 2 or 3 visits, these visits will need to be within 1 month of each other.

Compensation for all study visits: Yes

We have no studies currently recruiting in this area.